Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL

Kotaro Yokote, President of the Japan Society for the Study of Obesity Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) was approved in Japan earlier this month as the first obesity drug in some 30 years. Kotaro Yokote, president of the...read more